Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Lille
About this trial
This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.
Eligibility criteria
Qualifiers
Adults (≥ 18 years)
Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist
Disqualifiers
Patients under legal protection
Patients refusing the reuse of their data after individual information
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
University Hospital, Lille
Lead sponsor
Pfizer
Collaborator
Source ClinicalTrials.gov